Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Operating Leases (2022 - 2025)

Historic Operating Leases for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $43.3 million.

  • Immunocore Holdings' Operating Leases rose 214.08% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year increase of 214.08%. This contributed to the annual value of $40.2 million for FY2024, which is 1277.98% up from last year.
  • As of Q3 2025, Immunocore Holdings' Operating Leases stood at $43.3 million, which was up 214.08% from $44.4 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Operating Leases registered a high of $44.4 million during Q2 2025, and its lowest value of $31.8 million during Q4 2022.
  • In the last 4 years, Immunocore Holdings' Operating Leases had a median value of $40.2 million in 2024 and averaged $38.9 million.
  • Data for Immunocore Holdings' Operating Leases shows a peak YoY increase of 2748.05% (in 2025) and a maximum YoY decrease of 214.08% (in 2025) over the last 5 years.
  • Immunocore Holdings' Operating Leases (Quarter) stood at $31.8 million in 2022, then increased by 12.13% to $35.6 million in 2023, then rose by 12.78% to $40.2 million in 2024, then grew by 7.75% to $43.3 million in 2025.
  • Its Operating Leases was $43.3 million in Q3 2025, compared to $44.4 million in Q2 2025 and $42.5 million in Q1 2025.